Second Multiprofile Hospital For Active Treatment - Sofia EAD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Second Multiprofile Hospital For Active Treatment - Sofia EAD, the cardiology clinic is running studies in cardiovascular diseases focused on improving care for people with atrial fibrillation, acute coronary syndrome, acute myocardial infarction, and chronic heart failure. These trials are mainly designed to test new treatment options, reduce major heart and vascular events, and support better prevention after serious cardiac episodes.
- Testing therapies to prevent stroke and other clot-related complications in atrial fibrillation
- Evaluating approaches to lower recurrent events after acute myocardial infarction and acute coronary syndrome
- Studying treatment strategies for chronic heart failure, including care for iron-deficient patients
These projects reflect a strong focus on safer, more effective cardiovascular prevention and long-term management.
Digestive System Diseases
The site also supports research in digestive system diseases, especially Crohn's disease and ulcerative colitis. The studies aim to improve symptom control, help more patients reach clinical remission, and assess how well newer therapies work and are tolerated in both short- and long-term treatment settings.
- Investigating treatments for moderately to severely active Crohn's disease
- Assessing therapies for moderately to severely active ulcerative colitis
- Exploring options for mild to moderate left-sided ulcerative colitis
Research in this area includes both induction and maintenance treatment goals, with attention to sustained disease control and patient quality of life.
Immune System Phenomena
Clinical trials in immune system phenomena at this hospital are centered on inflammatory bowel disease, where immune-driven inflammation plays a major role. The work is aimed at testing new immune-targeted therapies that may improve remission rates, reduce disease activity, and provide longer-lasting benefit for patients with chronic inflammatory conditions.
- Evaluating immune-targeted therapies for ulcerative colitis
- Studying inflammation control in Crohn's disease
- Assessing long-term safety and tolerability of newer biologic treatments
This area highlights the clinic’s role in advancing treatment for conditions driven by abnormal immune responses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Second Multiprofile Hospital For Active Treatment - Sofia EAD
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 2 | Unknown | 2023-08-23 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.